2 days ago
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback in June as momentum waned and investors anticipated potential interest rate hikes by the Federal Reserve. Growth and AI stocks outperformed value stocks, while large-cap companies generally surpassed small- and mid-cap stocks. Underperformance was noted in healthcare and communication services, while industrials, particularly in aerospace and defense, contributed positively to performance. The fund's investor class returned 16.38%, slightly below the Russell 1000 Growth Index's 16.74%. The investment approach focuses on bottom-up financial ***** ysis to identify large-cap companies with long-term earnings growth potential, while aiming to mitigate non-financial risks. Please review the Fund's top five holdings to gain insights into its key selections for 2026.
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company that discovers and commercializes therapeutics based on ribonucleic acid interference, detracted from the Fund's performance this quarter. On September 09, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $258.00 per share. Over the past month, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) returned 13.60%, but its shares are down 44.94% over the past year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $34.52 billion, and its stock has traded within a 52-week range of $197.81 to $495.55.
American Century Investments Focused Dynamic Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its Q2 2026 investor letter:
"Stock choices and a sector overweight relative to the benchmark detracted as many biotechnology stocks, including Alnylam Pharmaceuticals and Insmed, underperformed the market. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The biotechnology company's stock underperformed amid concerns of its upcoming late-stage clinical trial readouts despite what we believed was its otherwise strong recent financial performance."
#alny #century
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company that discovers and commercializes therapeutics based on ribonucleic acid interference, detracted from the Fund's performance this quarter. On September 09, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $258.00 per share. Over the past month, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) returned 13.60%, but its shares are down 44.94% over the past year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $34.52 billion, and its stock has traded within a 52-week range of $197.81 to $495.55.
American Century Investments Focused Dynamic Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its Q2 2026 investor letter:
"Stock choices and a sector overweight relative to the benchmark detracted as many biotechnology stocks, including Alnylam Pharmaceuticals and Insmed, underperformed the market. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The biotechnology company's stock underperformed amid concerns of its upcoming late-stage clinical trial readouts despite what we believed was its otherwise strong recent financial performance."
#alny #century
2 months ago
2026 has marked a significant turning point in biotech capital markets, not just a small comeback. Venture funding for biotech startups reached $9.1 billion in the first half of the year, the highest first-half total since 2022, while 13 biotech IPOs raised a combined $4.5 billion, with a median haul of nearly $302 million per offering, unusually high by recent standards, with the majority of this year's debutants still trading above their offering price. Dealmaking has also maintained its pace, with 38 acquisitions closing in the same time period, placing the industry at its fastest M&A pace in at least seven years.
Underneath that broad comeback is a more unique validation story for RNA interference in particular. The market for RNAi treatments is expected to rise from $2.9 billion in 2025 to $3.6 billion in 2026. This growth comes after RNAi spent nearly two decades as a research curiosity before receiving its first licensed medicine in 2018. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has recently emerged as the clearest example of this transition, and the market's reaction raises the question of whether the story has been properly priced.
During Q1 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) exceeded $1 billion in quarterly product revenue for the first time in its history, with $1.036 billion in net product revenue, up 121% year-over-year and 4% sequentially over Q4 2025, on total revenue of $1.17 billion, up 96% year-over-year. AMVUTTRA alone delivered $890 million, bringing total TTR franchise revenue (AMVUTTRA plus ONPATTRO) to $910 million, up 153% from the previous year.
That growth completely flipped the company's bottom line: GAAP net income was $206 million, compared to a $15.9 million loss in the same quarter the previous year, and GAAP income from operations came in at $268.6 million, up from a prior-year loss. A company that continued to burn cash a year ago is now solidly profitable on a GAAP basis.
The growth is also not driven by a single medicine, which is important for long-term viability. The rare disease franchise, GIVLAARI and OXLUMO, added $126 million, increasing 15% year-over-year, while AMVUTTRA's worldwide rollout has reached seven markets, with payment negotiations still ongoing in the Spanish and French markets. This means that a significant portion of the revenue base is yet to be released.
#revenue #first #gaap #markets
Underneath that broad comeback is a more unique validation story for RNA interference in particular. The market for RNAi treatments is expected to rise from $2.9 billion in 2025 to $3.6 billion in 2026. This growth comes after RNAi spent nearly two decades as a research curiosity before receiving its first licensed medicine in 2018. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has recently emerged as the clearest example of this transition, and the market's reaction raises the question of whether the story has been properly priced.
During Q1 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) exceeded $1 billion in quarterly product revenue for the first time in its history, with $1.036 billion in net product revenue, up 121% year-over-year and 4% sequentially over Q4 2025, on total revenue of $1.17 billion, up 96% year-over-year. AMVUTTRA alone delivered $890 million, bringing total TTR franchise revenue (AMVUTTRA plus ONPATTRO) to $910 million, up 153% from the previous year.
That growth completely flipped the company's bottom line: GAAP net income was $206 million, compared to a $15.9 million loss in the same quarter the previous year, and GAAP income from operations came in at $268.6 million, up from a prior-year loss. A company that continued to burn cash a year ago is now solidly profitable on a GAAP basis.
The growth is also not driven by a single medicine, which is important for long-term viability. The rare disease franchise, GIVLAARI and OXLUMO, added $126 million, increasing 15% year-over-year, while AMVUTTRA's worldwide rollout has reached seven markets, with payment negotiations still ongoing in the Spanish and French markets. This means that a significant portion of the revenue base is yet to be released.
#revenue #first #gaap #markets
2 months ago
July 10, 2026 6:15 am ET
Listen
(3 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1622 GMT – The failure of Wainua, a heart disease drug developed by AstraZeneca and Ionis, to meet a primary endpoint in a phase 3 trial is a positive for both BridgeBio Pharma and Alnylam Pharmaceuticals, according to Jefferies **** ysts. For BridgeBio, the news is a potential clearing event for its Attruby drug, an oral stabilizer that addresses the same rare heart disease known as transthyretin amyloid cardiomyopathy. It’s also a headwind for Alnylam, whose Amvuttra treatment will remain the only gene silencer for ATTR-CM, the **** ysts write, although long-term questions remain for the company’s next-generation silencer. Alnylam stock is up 2.4%, erasing some gains after opening up 16%. BridgeBio shares gain 15%. (elias.schisgallwsj.com)
Listen
(3 min)
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1622 GMT – The failure of Wainua, a heart disease drug developed by AstraZeneca and Ionis, to meet a primary endpoint in a phase 3 trial is a positive for both BridgeBio Pharma and Alnylam Pharmaceuticals, according to Jefferies **** ysts. For BridgeBio, the news is a potential clearing event for its Attruby drug, an oral stabilizer that addresses the same rare heart disease known as transthyretin amyloid cardiomyopathy. It’s also a headwind for Alnylam, whose Amvuttra treatment will remain the only gene silencer for ATTR-CM, the **** ysts write, although long-term questions remain for the company’s next-generation silencer. Alnylam stock is up 2.4%, erasing some gains after opening up 16%. BridgeBio shares gain 15%. (elias.schisgallwsj.com)
3 months ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the most promising healthcare stocks according to Wall Street **** ysts. On June 10, GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to cover four Nordic countries, that is, Sweden, Finland, Denmark, and Norway. GENESIS is an Athens-based biopharma company and the expanded collaboration gives it rights to commercialize Alnylam's RNAi therapeutics for serious heart muscle diseases and rare genetic conditions across the new territory.
The two companies started to work together in 2019, and at that time, the collaboration only covered Southeast Europe. Without the four additional countries, the collaboration covers 13 markets.
RNAi, or RNA interference, is Alnylam's proprietary technology that silences the genes responsible for producing disease-causing proteins. In short, it works by cutting off diseases at a molecular level before they fully take hold. This technology is a key part of the company's portfolio.
The expanded relationship means that Alnylam now has four new markets for the technology. According to Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, the expansion also means that the company "can continue to address the needs of even more patients and their families."
For Constantinos Evripides, Managing Director of GENESIS, the expanded relationship is an important push the company needed to strengthen their European footprint. "By combining Alnylam's pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems," Evripides said.
The two companies started to work together in 2019, and at that time, the collaboration only covered Southeast Europe. Without the four additional countries, the collaboration covers 13 markets.
RNAi, or RNA interference, is Alnylam's proprietary technology that silences the genes responsible for producing disease-causing proteins. In short, it works by cutting off diseases at a molecular level before they fully take hold. This technology is a key part of the company's portfolio.
The expanded relationship means that Alnylam now has four new markets for the technology. According to Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, the expansion also means that the company "can continue to address the needs of even more patients and their families."
For Constantinos Evripides, Managing Director of GENESIS, the expanded relationship is an important push the company needed to strengthen their European footprint. "By combining Alnylam's pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems," Evripides said.
